{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:19:25Z","timestamp":1791271165393,"version":"4.1.0"},"reference-count":154,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1016\/j.parkreldis.2007.06.015","type":"journal-article","created":{"date-parts":[[2007,10,5]],"date-time":"2007-10-05T07:12:24Z","timestamp":1191568344000},"page":"466-479","source":"Crossref","is-referenced-by-count":49,"title":["Relating mode of action to clinical practice: Dopaminergic agents in Parkinson's disease"],"prefix":"10.1016","volume":"13","author":[{"given":"Peter","family":"Riederer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Gerlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Reichmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2007.06.015_bib1","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1007\/BF01485901","article-title":"Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system.","volume":"38","author":"Ehringer","year":"1960","journal-title":"Klin Wochenschr"},{"issue":"1","key":"10.1016\/j.parkreldis.2007.06.015_bib2","first-page":"25","article-title":"Drugs in development for Parkinson's disease: an update","volume":"7","author":"Johnston","year":"2006","journal-title":"Curr Opin Invest Drugs"},{"issue":"9","key":"10.1016\/j.parkreldis.2007.06.015_bib3","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2165\/00023210-200519090-00001","article-title":"Treatment of Parkinson's disease: what's on the horizon?","volume":"19","author":"Wu","year":"2005","journal-title":"CNS Drugs"},{"issue":"11 (Suppl 5)","key":"10.1016\/j.parkreldis.2007.06.015_bib4","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1212\/WNL.56.suppl_5.S1","article-title":"An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines","volume":"56","author":"Olanow","year":"2001","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.parkreldis.2007.06.015_bib5","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/mds.20243","article-title":"Levodopa in the treatment of Parkinson's disease: current controversies","volume":"19","author":"Olanow","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2007.06.015_bib6","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1146\/annurev.pa.33.040193.001433","article-title":"Molecular diversity of the dopamine receptors","volume":"33","author":"Civelli","year":"1993","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"3","key":"10.1016\/j.parkreldis.2007.06.015_bib7","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.pharmthera.2005.12.001","article-title":"What has been learnt from study of dopamine receptors in Parkinson's disease?","volume":"111","author":"Hurley","year":"2006","journal-title":"Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.parkreldis.2007.06.015_bib8","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1001\/archneur.61.11.1705","article-title":"Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease: a positron emission tomographic study","volume":"61","author":"Thobois","year":"2004","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/j.parkreldis.2007.06.015_bib9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/mds.870120107","article-title":"Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride","volume":"12","author":"Antonini","year":"1997","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2007.06.015_bib10","first-page":"787","article-title":"The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia","volume":"73","author":"Birkmayer","year":"1961","journal-title":"Wien Klin Wochenschr"},{"issue":"12","key":"10.1016\/j.parkreldis.2007.06.015_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.20.12_Part_2.1","article-title":"Physiologic, biochemical, and pathological backgrounds of levodopa and possibilities for the future","volume":"20","author":"Hornykiewicz","year":"1970","journal-title":"Neurology"},{"issue":"13","key":"10.1016\/j.parkreldis.2007.06.015_bib12","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1001\/jama.218.13.1903","article-title":"Levodopa in the treatment of Parkinsonism","volume":"218","author":"Cotzias","year":"1971","journal-title":"J Am Med Assos"},{"issue":"1","key":"10.1016\/j.parkreldis.2007.06.015_bib13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF01217333","article-title":"Further experimental studies on the catecholamine metabolism in extrapyramidal diseases (Parkinson and chorea syndromes)","volume":"210","author":"Birkmayer","year":"1967","journal-title":"Arch Psychiatr Nervenkr"},{"issue":"7","key":"10.1016\/j.parkreldis.2007.06.015_bib14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.tips.2005.05.002","article-title":"The \u2018magic\u2019 of L-dopa: why is it the gold standard Parkinson's disease therapy?","volume":"26","author":"Mercuri","year":"2005","journal-title":"Trends Pharmacol Sci"},{"issue":"12","key":"10.1016\/j.parkreldis.2007.06.015_bib15","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1523\/JNEUROSCI.20-12-04405.2000","article-title":"Dopamine-deficient mice are hypersensitive to dopamine receptor agonists","volume":"20","author":"Kim","year":"2000","journal-title":"J Neurosci"},{"issue":"36","key":"10.1016\/j.parkreldis.2007.06.015_bib16","doi-asserted-by":"crossref","first-page":"13329","DOI":"10.1073\/pnas.0405084101","article-title":"Firing properties of dopamine neurons in freely moving dopamine-deficient mice: effects of dopamine receptor activation and anesthesia","volume":"101","author":"Robinson","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.parkreldis.2007.06.015_bib17","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.brainres.2005.08.053","article-title":"Dysregulation of dopamine signaling in the dorsal striatum inhibits feeding","volume":"1061","author":"Sotak","year":"2005","journal-title":"Brain Res"},{"issue":"3","key":"10.1016\/j.parkreldis.2007.06.015_bib18","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.neuron.2004.10.009","article-title":"Dysregulation of striatal dopamine signaling by amphetamine inhibits feeding by hungry mice","volume":"44","author":"Cannon","year":"2004","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.parkreldis.2007.06.015_bib19","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0306-4522(00)00588-1","article-title":"Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum","volume":"103","author":"Lopez","year":"2001","journal-title":"Neuroscience"},{"issue":"5","key":"10.1016\/j.parkreldis.2007.06.015_bib20","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1046\/j.1471-4159.2003.02109.x","article-title":"Real-time decoding of dopamine concentration changes in the caudate-putamen during tonic and phasic firing","volume":"87","author":"Venton","year":"2003","journal-title":"J Neurochem"},{"issue":"1","key":"10.1016\/j.parkreldis.2007.06.015_bib21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ana.20296","article-title":"Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia","volume":"57","author":"Aubert","year":"2005","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.parkreldis.2007.06.015_bib22","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/mds.870090613","article-title":"The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys","volume":"9","author":"Vermeulen","year":"1994","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"10.1016\/j.parkreldis.2007.06.015_bib23","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00019052-200312001-00002","article-title":"Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease","volume":"16","author":"Jenner","year":"2003","journal-title":"Curr Opin Neurol"},{"issue":"4","key":"10.1016\/j.parkreldis.2007.06.015_bib24","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/1531-8257(200007)15:4<613::AID-MDS1005>3.0.CO;2-F","article-title":"Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients","volume":"15","author":"Kulisevsky","year":"2000","journal-title":"Mov Disord"},{"issue":"Pt 3","key":"10.1016\/j.parkreldis.2007.06.015_bib25","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/brain\/awf052","article-title":"Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET","volume":"125","author":"Cools","year":"2002","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.parkreldis.2007.06.015_bib26","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1046\/j.1460-9568.1998.00145.x","article-title":"Reduction of noradrenaline impairs attention and dopamine depletion slows responses in Parkinson's disease","volume":"10","author":"Riekkinen","year":"1998","journal-title":"Eur J Neurosci"},{"issue":"Pt 1","key":"10.1016\/j.parkreldis.2007.06.015_bib27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1113\/jphysiol.2001.013938","article-title":"Dopamine selectively reduces GABA(B) transmission onto dopaminergic neurones by an unconventional presynaptic action","volume":"540","author":"Federici","year":"2002","journal-title":"J Physiol"},{"issue":"1\u20132","key":"10.1016\/j.parkreldis.2007.06.015_bib28","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0006-8993(98)00336-9","article-title":"Dopaminergic regulation of serotonin release in the substantia nigra of the freely moving rat using microdialysis","volume":"796","author":"Thorre","year":"1998","journal-title":"Brain Res"},{"issue":"1","key":"10.1016\/j.parkreldis.2007.06.015_bib29","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.neuroscience.2004.07.043","article-title":"Differential contribution of dopamine D2S and D2L receptors in the modulation of glutamate and GABA transmission in the striatum","volume":"129","author":"Centonze","year":"2004","journal-title":"Neuroscience"},{"issue":"45","key":"10.1016\/j.parkreldis.2007.06.015_bib30","doi-asserted-by":"crossref","first-page":"10537","DOI":"10.1523\/JNEUROSCI.2959-05.2005","article-title":"Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum","volume":"25","author":"Kreitzer","year":"2005","journal-title":"J Neurosci"},{"issue":"4","key":"10.1016\/j.parkreldis.2007.06.015_bib31","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1212\/WNL.50.4.858","article-title":"Levodopa: is toxicity a myth?","volume":"50","author":"Agid","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2007.06.015_bib32","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/jnr.490260405","article-title":"Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture","volume":"26","author":"Michel","year":"1990","journal-title":"J Neurosci Res"},{"issue":"2","key":"10.1016\/j.parkreldis.2007.06.015_bib33","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0014-4886(90)90031-M","article-title":"Chronic levodopa impairs morphological development of grafted embryonic dopamine neurons","volume":"110","author":"Steece-Collier","year":"1990","journal-title":"Exp Neurol"},{"key":"10.1016\/j.parkreldis.2007.06.015_bib34","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/j.1471-4159.1993.tb13642.x","article-title":"Toxic and protective effects of L-DOPA on mesencephalic cell cultures","volume":"61","author":"Mytilineou","year":"1993","journal-title":"J Neurochem"},{"issue":"4\u20135","key":"10.1016\/j.parkreldis.2007.06.015_bib35","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/BF01277654","article-title":"Glia protect fetal midbrain dopamine neurons in culture from L-DOPA toxicity through multiple mechanisms","volume":"104","author":"Mena","year":"1997","journal-title":"J Neural Transm"},{"issue":"4","key":"10.1016\/j.parkreldis.2007.06.015_bib36","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1046\/j.1471-4159.1997.69041398.x","article-title":"Neurotrophic effects of L-DOPA in postnatal midbrain dopamine neuron\/cortical astrocyte cocultures","volume":"69","author":"Mena","year":"1997","journal-title":"J Neurochem"},{"issue":"4","key":"10.1016\/j.parkreldis.2007.06.015_bib37","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0026-895X(24)13069-6","article-title":"A synergistic neurotrophic response to l-dihydroxyphenylalanine and nerve growth factor","volume":"54","author":"Mena","year":"1998","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.parkreldis.2007.06.015_bib38","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1471-4159.1984.tb12834.x","article-title":"Nigrostriatal dopaminergic neurons remain undamaged in rats gien high doses of L-DOPA and carbidopa chronically","volume":"43","author":"Perry","year":"1984","journal-title":"J Neurochem"},{"issue":"5","key":"10.1016\/j.parkreldis.2007.06.015_bib39","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/ana.410430504","article-title":"Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions","volume":"43","author":"Murer","year":"1998","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.parkreldis.2007.06.015_bib40","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1212\/WNL.32.6.684","article-title":"Chronic dopa feeding of mice","volume":"32","author":"Reches","year":"1982","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.parkreldis.2007.06.015_bib41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s702-002-8236-2","article-title":"Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys","volume":"109","author":"Lyras","year":"2002","journal-title":"J Neural Transm"},{"issue":"4","key":"10.1016\/j.parkreldis.2007.06.015_bib42","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s002130100733","article-title":"L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations","volume":"156","author":"Pearce","year":"2001","journal-title":"Psychopharmacology (Berlin)"},{"issue":"2","key":"10.1016\/j.parkreldis.2007.06.015_bib43","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/mds.870080202","article-title":"Suppressive effect of l-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine","volume":"8","author":"Blunt","year":"1993","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.parkreldis.2007.06.015_bib44","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/mds.1091","article-title":"Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions","volume":"16","author":"Datla","year":"2001","journal-title":"Mov Disord"},{"issue":"24","key":"10.1016\/j.parkreldis.2007.06.015_bib45","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","article-title":"Levodopa and the progression of Parkinson's disease","volume":"351","author":"Fahn","year":"2004","journal-title":"N Engl J Med"},{"issue":"1\u20132","key":"10.1016\/j.parkreldis.2007.06.015_bib46","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0006-8993(94)91872-4","article-title":"The effects of chronic continuous dopamine receptors and dopamine uptake sites in the 6-hydroxydopamine lesioned rat\u2014an autoradiographic study","volume":"640","author":"Gnanalingham","year":"1994","journal-title":"Brain Res"},{"issue":"1","key":"10.1016\/j.parkreldis.2007.06.015_bib47","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0014-2999(95)00770-9","article-title":"Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter","volume":"298","author":"Gordon","year":"1996","journal-title":"Eur J Pharmacol"},{"issue":"8007","key":"10.1016\/j.parkreldis.2007.06.015_bib48","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(77)91146-1","article-title":"Success and problems of long-term levodopa therapy in Parkinson's disease","volume":"1","author":"Marsden","year":"1977","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.parkreldis.2007.06.015_bib49","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S1474-4422(06)70521-X","article-title":"Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications","volume":"5","author":"Olanow","year":"2006","journal-title":"Lancet Neurol"},{"issue":"1 (Suppl. 1)","key":"10.1016\/j.parkreldis.2007.06.015_bib50","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1212\/WNL.62.1_suppl_1.S17","article-title":"The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits","volume":"62","author":"Obeso","year":"2004","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.parkreldis.2007.06.015_bib51","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1006\/phrs.2001.0819","article-title":"Monitoring of L-dopa concentrations in Parkinson's disease","volume":"43","author":"Furlanut","year":"2001","journal-title":"Pharmacol Res"},{"issue":"1","key":"10.1016\/j.parkreldis.2007.06.015_bib52","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.expneurol.2004.03.004","article-title":"The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease","volume":"188","author":"Nakao","year":"2004","journal-title":"Exp Neurol"},{"issue":"3","key":"10.1016\/j.parkreldis.2007.06.015_bib53","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/ana.410240303","article-title":"Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I","volume":"24","author":"Fabbrini","year":"1988","journal-title":"Ann Neurol"},{"issue":"8","key":"10.1016\/j.parkreldis.2007.06.015_bib54","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1212\/WNL.34.8.1105","article-title":"Altered pharmacokinetics of L-dopa metabolism in rat striatum deprived of dopaminergic innervation","volume":"34","author":"Spencer","year":"1984","journal-title":"Neurology"},{"issue":"11 (Suppl. 4)","key":"10.1016\/j.parkreldis.2007.06.015_bib55","first-page":"S72","article-title":"Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors","volume":"55","author":"Olanow","year":"2000","journal-title":"Neurology"},{"issue":"10 Suppl","key":"10.1016\/j.parkreldis.2007.06.015_bib56","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/S1471-1931(00)00030-6","article-title":"Continuous dopamine-receptor stimulation in early Parkinson's disease","volume":"23","author":"Olanow","year":"2000","journal-title":"Trends Neurosci"},{"issue":"1","key":"10.1016\/j.parkreldis.2007.06.015_bib57","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/0006-8993(90)91318-B","article-title":"Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats","volume":"525","author":"Abercrombie","year":"1990","journal-title":"Brain Res"},{"issue":"3","key":"10.1016\/j.parkreldis.2007.06.015_bib58","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.65","article-title":"Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover","volume":"49","author":"de la Fuente-Fernandez","year":"2001","journal-title":"Ann Neurol"},{"issue":"4 (Suppl 1)","key":"10.1016\/j.parkreldis.2007.06.015_bib59","first-page":"S70","article-title":"Molecular basis of levodopa-induced dyskinesias","volume":"47","author":"Calon","year":"2000","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.parkreldis.2007.06.015_bib60","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/jnen\/61.2.186","article-title":"Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias","volume":"61","author":"Calon","year":"2002","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1-2","key":"10.1016\/j.parkreldis.2007.06.015_bib61","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0169-328X(97)00123-X","article-title":"Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy","volume":"49","author":"Morissette","year":"1997","journal-title":"Brain Res Mol Brain Res"},{"issue":"2","key":"10.1016\/j.parkreldis.2007.06.015_bib62","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0306-4522(99)00294-8","article-title":"Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment","volume":"94","author":"Cenci","year":"1999","journal-title":"Neuroscience"},{"issue":"10 Suppl","key":"10.1016\/j.parkreldis.2007.06.015_bib63","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/S1471-1931(00)00027-6","article-title":"Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis","volume":"23","author":"Graybiel","year":"2000","journal-title":"Trends Neurosci"},{"issue":"4 Suppl 1","key":"10.1016\/j.parkreldis.2007.06.015_bib64","first-page":"S53","article-title":"Patterns of gene expression and behavior induced by chronic dopamine treatments","volume":"47","author":"Canales","year":"2000","journal-title":"Ann Neurol"},{"issue":"4 (Suppl. 1)","key":"10.1016\/j.parkreldis.2007.06.015_bib65","first-page":"S22","article-title":"Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model","volume":"47","author":"Obeso","year":"2000","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.parkreldis.2007.06.015_bib66","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/mds.20435","article-title":"Levodopa in the treatment of Parkinson's disease: current controversies","volume":"20","author":"Gerlach","year":"2005","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.parkreldis.2007.06.015_bib67","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1006\/exnr.2002.8055","article-title":"Both short- and long-acting D-1\/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus)","volume":"179","author":"Maratos","year":"2003","journal-title":"Exp Neurol"},{"issue":"3","key":"10.1016\/j.parkreldis.2007.06.015_bib68","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1212\/WNL.39.3.336","article-title":"Lisuride, a dopamine agonist in the treatment of early Parkinson's disease","volume":"39","author":"Rinne","year":"1989","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.parkreldis.2007.06.015_bib69","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/archneur.62.6.905","article-title":"Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study","volume":"62","author":"Stocchi","year":"2005","journal-title":"Arch Neurol"},{"issue":"6","key":"10.1016\/j.parkreldis.2007.06.015_bib70","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1212\/WNL.40.6.995","article-title":"Sustained enteral administration of levodopa increases and interrupted infusion decreases levodopa dose requirements","volume":"40","author":"Cedarbaum","year":"1990","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.parkreldis.2007.06.015_bib71","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00002826-198906000-00001","article-title":"The promise and limitations of controlled-release oral levodopa administration","volume":"12","author":"Cedarbaum","year":"1989","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"10.1016\/j.parkreldis.2007.06.015_bib72","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1212\/WNL.53.5.1012","article-title":"Immediate-release and controlled-release carbidopa\/levodopa in PD: a 5-year randomized multicenter study. Carbidopa\/Levodopa Study Group.","volume":"53","author":"Koller","year":"1999","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.parkreldis.2007.06.015_bib73","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1600-0404.1996.tb00163.x","article-title":"Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients","volume":"93","author":"Dupont","year":"1996","journal-title":"Acta Neurol Scand"},{"issue":"9317","key":"10.1016\/j.parkreldis.2007.06.015_bib74","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/S0140-6736(02)08520-3","article-title":"Treatment interventions for Parkinson's disease: an evidence based assessment","volume":"359","author":"Rascol","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.parkreldis.2007.06.015_bib75","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1586\/14737175.4.4.589","article-title":"Clinical experience with the novel levodopa formulation entacapone+levodopa+carbidopa (Stalevo)","volume":"4","author":"Silver","year":"2004","journal-title":"Expert Rev Neurother"},{"issue":"10\u201311","key":"10.1016\/j.parkreldis.2007.06.015_bib76","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00702-004-0190-3","article-title":"Clinical advantages of COMT inhibition with entacapone\u2014a review","volume":"111","author":"Gordin","year":"2004","journal-title":"J Neural Transm"},{"issue":"Suppl 1","key":"10.1016\/j.parkreldis.2007.06.015_bib77","first-page":"267","article-title":"The efficacy and safety of COMT inhibition in clinical trials in Parkinson's disease","volume":"11","author":"Gordin","year":"1996","journal-title":"Mov Disord"},{"issue":"6","key":"10.1016\/j.parkreldis.2007.06.015_bib78","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1474-4422(05)70098-3","article-title":"Entacapone in the treatment of Parkinson's disease","volume":"4","author":"Schrag","year":"2005","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.parkreldis.2007.06.015_bib79","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00002826-199619040-00001","article-title":"A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease","volume":"19","author":"Ruottinen","year":"1996","journal-title":"Clin Neuropharmacol"},{"issue":"11 (Suppl 4)","key":"10.1016\/j.parkreldis.2007.06.015_bib80","first-page":"S33","article-title":"Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients","volume":"55","author":"Nutt","year":"2000","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.parkreldis.2007.06.015_bib81","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s00210-004-0984-8","article-title":"Entacapone increases and prolongs the central effects of l-DOPA in the 6-hydroxydopamine-lesioned rat","volume":"370","author":"Gerlach","year":"2004","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"3","key":"10.1016\/j.parkreldis.2007.06.015_bib82","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/mds.20717","article-title":"Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels","volume":"21","author":"Muller","year":"2006","journal-title":"Mov Disord"},{"issue":"8","key":"10.1016\/j.parkreldis.2007.06.015_bib83","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1136\/jnnp.74.8.1071","article-title":"Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study","volume":"74","author":"Brooks","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.parkreldis.2007.06.015_bib84","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1212\/WNL.51.5.1309","article-title":"Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group.","volume":"51","author":"Rinne","year":"1998","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.parkreldis.2007.06.015_bib85","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1034\/j.1600-0404.2002.1o174.x","article-title":"Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study)","volume":"105","author":"Poewe","year":"2002","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"10.1016\/j.parkreldis.2007.06.015_bib86","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/mds.20317","article-title":"Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates","volume":"20","author":"Smith","year":"2004","journal-title":"Mov Disord"},{"issue":"Suppl 13","key":"10.1016\/j.parkreldis.2007.06.015_bib87","first-page":"S111","article-title":"Early initiation of entacapone leads to superior 5-year efficacy compared to delayed initiation in Parkinson's disease patients receiving traditional levodopa\/DDCI therapy","volume":"21","author":"Nissinen","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2007.06.015_bib88","doi-asserted-by":"crossref","DOI":"10.1212\/01.wnl.0000215250.82576.87","article-title":"Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology","author":"Pahwa","year":"2006","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.parkreldis.2007.06.015_bib89","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrn1883","article-title":"The therapeutic potential of monoamine oxidase inhibitors","volume":"7","author":"Youdim","year":"2006","journal-title":"Nat Rev Neurosci"},{"issue":"5235","key":"10.1016\/j.parkreldis.2007.06.015_bib90","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/225817a0","article-title":"Multiple forms of human brain mitochondrial monoamine oxidase","volume":"225","author":"Collins","year":"1970","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.parkreldis.2007.06.015_bib91","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/BF00500765","article-title":"The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions","volume":"322","author":"O\u2019Carroll","year":"1983","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"5","key":"10.1016\/j.parkreldis.2007.06.015_bib92","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/j.1471-4159.1986.tb01747.x","article-title":"Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl","volume":"46","author":"Riederer","year":"1986","journal-title":"J Neurochem"},{"issue":"7 (Suppl 2)","key":"10.1016\/j.parkreldis.2007.06.015_bib93","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1212\/WNL.63.7_suppl_2.S32","article-title":"A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease","volume":"63","author":"Youdim","year":"2004","journal-title":"Neurology"},{"issue":"7466","key":"10.1016\/j.parkreldis.2007.06.015_bib94","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1136\/bmj.38184.606169.AE","article-title":"Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients","volume":"329","author":"Ives","year":"2004","journal-title":"Br Med J"},{"issue":"8","key":"10.1016\/j.parkreldis.2007.06.015_bib95","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1212\/01.wnl.0000204007.46190.54","article-title":"Selegiline slows the progression of the symptoms of Parkinson disease","volume":"66","author":"Palhagen","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2007.06.015_bib96","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ana.410390106","article-title":"Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa","volume":"39","author":"Parkinson","year":"1996","journal-title":"Ann Neurol"},{"issue":"12","key":"10.1016\/j.parkreldis.2007.06.015_bib97","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1001\/archneur.59.12.1937","article-title":"A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study","volume":"59","author":"Group","year":"2002","journal-title":"Arch Neurol"},{"issue":"5985","key":"10.1016\/j.parkreldis.2007.06.015_bib98","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/311467a0","article-title":"Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors","volume":"311","author":"Heikkila","year":"1984","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.parkreldis.2007.06.015_bib99","doi-asserted-by":"crossref","first-page":"R3","DOI":"10.1016\/0922-4106(94)90048-5","article-title":"Selegiline enhances survival and neurite outgrowth of MPP(+)-treated dopaminergic neurons","volume":"269","author":"Koutsilieri","year":"1994","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.parkreldis.2007.06.015_bib100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1046\/j.1471-4159.1997.68010033.x","article-title":"L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro","volume":"68","author":"Mytilineou","year":"1997","journal-title":"J Neurochem"},{"issue":"2","key":"10.1016\/j.parkreldis.2007.06.015_bib101","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1124\/jpet.301.2.753","article-title":"Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells","volume":"301","author":"Tatton","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.parkreldis.2007.06.015_bib102","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1749-6632.2001.tb03656.x","article-title":"The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo","volume":"939","author":"Youdim","year":"2001","journal-title":"Ann NY Acad Sci"},{"issue":"2","key":"10.1016\/j.parkreldis.2007.06.015_bib103","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0304-3940(02)00332-4","article-title":"An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells","volume":"326","author":"Akao","year":"2002","journal-title":"Neurosci Lett"},{"issue":"6","key":"10.1016\/j.parkreldis.2007.06.015_bib104","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1023\/A:1015131516649","article-title":"Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]","volume":"21","author":"Youdim","year":"2001","journal-title":"Cell Mol Neurobiol"},{"issue":"2","key":"10.1016\/j.parkreldis.2007.06.015_bib105","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF01245973","article-title":"Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study","volume":"64","author":"Birkmayer","year":"1985","journal-title":"J Neural Transm"},{"issue":"4917","key":"10.1016\/j.parkreldis.2007.06.015_bib106","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1126\/science.2502843","article-title":"The effect of deprenyl (selegiline) on the natural history of Parkinson's disease","volume":"245","author":"Tetrud","year":"1989","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.parkreldis.2007.06.015_bib107","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ana.410380512","article-title":"The effect of deprenyl and levodopa on the progression of Parkinson's disease","volume":"38","author":"Olanow","year":"1995","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.parkreldis.2007.06.015_bib108","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1468-1331.1999.tb00007.x","article-title":"SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa","volume":"6","author":"Przuntek","year":"1999","journal-title":"Eur J Neurol"},{"issue":"6","key":"10.1016\/j.parkreldis.2007.06.015_bib109","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/ana.410320614","article-title":"The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic","volume":"32","author":"Schulzer","year":"1992","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.parkreldis.2007.06.015_bib110","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/syn.890180203","article-title":"Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal","volume":"18","author":"Fowler","year":"1994","journal-title":"Synapse"},{"issue":"4","key":"10.1016\/j.parkreldis.2007.06.015_bib111","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1353-8020(01)00011-6","article-title":"Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease","volume":"8","author":"Youdim","year":"2002","journal-title":"Parkinsonism Relat Disord"},{"issue":"11","key":"10.1016\/j.parkreldis.2007.06.015_bib112","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00702-003-0036-4","article-title":"A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition","volume":"110","author":"Clarke","year":"2003","journal-title":"J Neural Transm"},{"issue":"11","key":"10.1016\/j.parkreldis.2007.06.015_bib113","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s00702-003-0083-x","article-title":"Selegiline's neuroprotective capacity revisited","volume":"110","author":"Riederer","year":"2003","journal-title":"J Neural Transm"},{"key":"10.1016\/j.parkreldis.2007.06.015_bib114","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1136\/bmj.311.7020.1602","article-title":"Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease","volume":"311","author":"Lees","year":"1995","journal-title":"Br Med J"},{"issue":"Suppl. 10","key":"10.1016\/j.parkreldis.2007.06.015_bib115","first-page":"S75","article-title":"Early treatment with rasagiline is more beneficial than delayed treatment start in the long-term management of Parkinson's disease","volume":"20","author":"Hauser","year":"2005","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.parkreldis.2007.06.015_bib116","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/ana.20789","article-title":"Timing of treatment initiation in Parkinson's disease: a need for reappraisal?","volume":"59","author":"Schapira","year":"2006","journal-title":"Ann Neurol"},{"issue":"7","key":"10.1016\/j.parkreldis.2007.06.015_bib117","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1212\/01.wnl.0000206363.57955.1b","article-title":"Practice parameter: neuroprotective strategies and alternative Quality Standards Subcommittee of the American Academy of Neurology","volume":"66","author":"Suchowersky","year":"2006","journal-title":"Neurology"},{"issue":"15","key":"10.1016\/j.parkreldis.2007.06.015_bib118","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1001\/jama.284.15.1931","article-title":"Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group","volume":"284","year":"2000","journal-title":"J Am Med Assn"},{"issue":"20","key":"10.1016\/j.parkreldis.2007.06.015_bib119","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group","volume":"342","author":"Rascol","year":"2000","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.parkreldis.2007.06.015_bib120","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/00023210-200418110-00003","article-title":"The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study","volume":"18","author":"Bracco","year":"2004","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.parkreldis.2007.06.015_bib121","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/mds.20724","article-title":"Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study","volume":"21","author":"Oertel","year":"2006","journal-title":"Mov Disord"},{"issue":"10\u201311","key":"10.1016\/j.parkreldis.2007.06.015_bib122","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00702-003-0059-x","article-title":"Dopamine receptor agonists in the therapy of Parkinson's disease","volume":"111","author":"Foley","year":"2004","journal-title":"J Neural Transm"},{"issue":"1","key":"10.1016\/j.parkreldis.2007.06.015_bib123","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1586\/14737175.6.1.81","article-title":"Dopamine agonists in the treatment of Parkinson's disease","volume":"6","author":"Bonuccelli","year":"2006","journal-title":"Expert Rev Neurother"},{"issue":"10","key":"10.1016\/j.parkreldis.2007.06.015_bib124","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00702-003-0027-5","article-title":"Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum","volume":"110","author":"Gerlach","year":"2003","journal-title":"J Neural Transm"},{"issue":"2","key":"10.1016\/j.parkreldis.2007.06.015_bib125","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1212\/WNL.53.2.364","article-title":"A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group","volume":"53","author":"Korczyn","year":"1999","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.parkreldis.2007.06.015_bib126","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s007020170097","article-title":"Switching from pergolide to pramipexole in patients with Parkinson's disease","volume":"108","author":"Hanna","year":"2001","journal-title":"J Neural Transm"},{"issue":"12","key":"10.1016\/j.parkreldis.2007.06.015_bib127","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/mds.20329","article-title":"Fibrotic valvular heart disease is not related to chemical class but to biological function: 5-HT2B receptor activation plays crucial role","volume":"19","author":"Horowski","year":"2004","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.parkreldis.2007.06.015_bib128","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00002826-200305000-00001","article-title":"Fibrosis associated with dopamine agonist therapy in Parkinson's disease","volume":"26","author":"Muller","year":"2003","journal-title":"Clin Neuropharmacol"},{"issue":"13","key":"10.1016\/j.parkreldis.2007.06.015_bib129","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2165\/00023210-200317130-00003","article-title":"Pramipexole in routine clinical practice: a prospective observational trial in Parkinson's disease","volume":"17","author":"Reichmann","year":"2003","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.parkreldis.2007.06.015_bib130","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1176\/appi.neuropsych.17.2.214","article-title":"Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole","volume":"17","author":"Lemke","year":"2005","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"Suppl. 1","key":"10.1016\/j.parkreldis.2007.06.015_bib131","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00003495-199855001-00004","article-title":"Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group","volume":"55","author":"Rinne","year":"1998","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.parkreldis.2007.06.015_bib132","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/mds.20724","article-title":"Pergolide versus levodopa monotherapy in early Parkinson's disease patients: the PELMOPET study","volume":"21","author":"Oertel","year":"2005","journal-title":"Mov Disord"},{"issue":"7","key":"10.1016\/j.parkreldis.2007.06.015_bib133","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/archneur.63.7.969","article-title":"Association of dopamine agonist use with impulse control disorders in Parkinson disease","volume":"63","author":"Weintraub","year":"2006","journal-title":"Arch Neurol"},{"issue":"3","key":"10.1016\/j.parkreldis.2007.06.015_bib134","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1212\/01.WNL.0000076478.45005.EC","article-title":"Pathological gambling associated with dopamine agonist therapy in Parkinson's disease","volume":"61","author":"Driver-Dunckley","year":"2003","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.parkreldis.2007.06.015_bib135","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1001\/archneur.62.9.noc50009","article-title":"Pathological gambling caused by drugs used to treat Parkinson disease","volume":"62","author":"Dodd","year":"2005","journal-title":"Arch Neurol"},{"issue":"6","key":"10.1016\/j.parkreldis.2007.06.015_bib136","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.parkreldis.2005.06.005","article-title":"Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy","volume":"11","author":"Klos","year":"2005","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"10.1016\/j.parkreldis.2007.06.015_bib137","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/jnnp.68.4.423","article-title":"Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies","volume":"68","author":"Giovannoni","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"10.1016\/j.parkreldis.2007.06.015_bib138","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/mds.20163","article-title":"Predictors of sudden onset of sleep in Parkinson's disease","volume":"19","author":"Korner","year":"2004","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.parkreldis.2007.06.015_bib139","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1389-9457(03)00116-3","article-title":"Sleep episodes in Parkinson's disease: more questions remain","volume":"4","author":"Comella","year":"2003","journal-title":"Sleep Med"},{"issue":"16","key":"10.1016\/j.parkreldis.2007.06.015_bib140","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1001\/jama.287.16.2076","article-title":"Sudden-onset sleep in Parkinson disease","volume":"287","author":"Frucht","year":"2002","journal-title":"J Am Med Assos"},{"issue":"90001","key":"10.1016\/j.parkreldis.2007.06.015_bib141","doi-asserted-by":"crossref","first-page":"71S","DOI":"10.1212\/WNL.58.suppl_1.S71","article-title":"Dopamine agonists and sleep in Parkinson's disease","volume":"58","author":"Cantor","year":"2002","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.parkreldis.2007.06.015_bib142","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1212\/WNL.52.9.1908","article-title":"Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole","volume":"52","author":"Frucht","year":"1999","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.parkreldis.2007.06.015_bib143","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1212\/WNL.48.2.363","article-title":"Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group","volume":"48","author":"Rinne","year":"1997","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1016\/j.parkreldis.2007.06.015_bib144","first-page":"A396","article-title":"Incidence of dyskinesia in a 10-year follow-up of patients with early parkinson's disease (PD) initially receiving ropinirole compared with L-dopa","volume":"64","author":"Korczyn","year":"2005","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.parkreldis.2007.06.015_bib145","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1001\/archneur.61.7.1044","article-title":"Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial","volume":"61","author":"Holloway","year":"2004","journal-title":"Arch Neurol"},{"issue":"9","key":"10.1016\/j.parkreldis.2007.06.015_bib146","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1212\/WNL.57.9.1687","article-title":"Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial","volume":"57","author":"Lees","year":"2001","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.parkreldis.2007.06.015_bib147","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/archneur.60.12.1721","article-title":"A controlled trial of rotigotine monotherapy in early Parkinson's disease","volume":"60","year":"2003","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/j.parkreldis.2007.06.015_bib148","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1212\/WNL.58.1.11","article-title":"Practice parameter: Initiation of treatment for Parkinson's disease: an evidence-based review: Report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"58","author":"Miyasaki","year":"2002","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.parkreldis.2007.06.015_bib149","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/BF01271230","article-title":"Early institution of bromocriptine in Parkinson's disease inhibits the PRADO study","volume":"103","author":"Przuntek","year":"1996","journal-title":"J Neural Transm"},{"issue":"Suppl 3","key":"10.1016\/j.parkreldis.2007.06.015_bib150","first-page":"A82","article-title":"The develoment of dyskinesias in Parkinson's-disease patients receiving ropinirole and given supplemental L-dopa","volume":"56","author":"Lang","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2007.06.015_bib151","article-title":"Impact of pramipexole on the onset of levodopa related dyskinesia (CALM-PD)","author":"Kieburtz","year":"2006","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.parkreldis.2007.06.015_bib152","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00002826-200203000-00006","article-title":"Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations","volume":"25","author":"Nyholm","year":"2002","journal-title":"Clin Neuropharmacol"},{"issue":"9463","key":"10.1016\/j.parkreldis.2007.06.015_bib153","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","article-title":"Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial","volume":"365","author":"Rascol","year":"2005","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.parkreldis.2007.06.015_bib154","first-page":"268","article-title":"The COMT inhibitor entacapone improves Parkinsonian features in fluctuating patients","volume":"11","year":"1996","journal-title":"Mov Disord"}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802007001150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802007001150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T07:08:22Z","timestamp":1737443302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802007001150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":154,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["S1353802007001150"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2007.06.015","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}